Genetics

Aroa Biosurgery’s Endoform® Platform Shown to Attract Stem Cells

Retrieved on: 
Wednesday, August 19, 2020
Health, Medical devices, Stem cells, Surgery, Genetics, Clinical trials, Biotechnology, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Developmental biology, Regenerative biomedicine, Tissue engineering, Stem-cell therapy

Aroas lead scientist for the study, Dr Sandi Dempsey, said the paper describes the ability of components found within the Endoform ECM platform technology to signal stem cells in laboratory models.

Key Points: 
  • Aroas lead scientist for the study, Dr Sandi Dempsey, said the paper describes the ability of components found within the Endoform ECM platform technology to signal stem cells in laboratory models.
  • Endoform contains a vast number of proteins that interact with a patients own cells to support the repair of damaged tissue in different ways.
  • This data suggests that one such mechanism occurs by recruiting stem cells from the surrounding healthy tissue to support soft tissue repair, Dr Dempsey says.
  • That we have shown Endoform attracts stem cells to the site of tissue damage goes one step further towards unlocking the full regenerative capacity of Endoform.

Calviri Appoints Michael Chambers to Board of Directors

Retrieved on: 
Tuesday, August 18, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Vaccination, Vaccine, Virology, Fargo, North Dakota, Calviri, Inc., Aldevron

announces today the appointment of Michael Chambers to the Calviri Board of Directors.

Key Points: 
  • announces today the appointment of Michael Chambers to the Calviri Board of Directors.
  • Until recently Chambers held the position of CEO at Aldevron (Fargo, ND); he remains Chairman of the Board.
  • Chambers broad experience and success in the biotechnology industry will contribute greatly to new trials as Calviri works toward its diagnostic and vaccine product goals.
  • I have known Michael for over 20 years and have been amazed at what he has accomplished at Aldevron.

AgilVax Progress Triggers $1.2 Million SBIR Fast-Track Grant to Advance Antibody-Based Therapy

Retrieved on: 
Tuesday, August 18, 2020
Research, Public relations, Investor relations, Genetics, Communications, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Amino acids, Organic compounds, Solute carrier family, Cystine/glutamate transporter, Biotechnology, Thiols, Cystine, Cysteine, Antibody-drug conjugate, Glutamate, Reactive oxygen species, Glutamate receptor

AgilVax successfully achieved its goals from the earlier phases allowing the final portion of the grant to be awarded.

Key Points: 
  • AgilVax successfully achieved its goals from the earlier phases allowing the final portion of the grant to be awarded.
  • AgilVax has three development programs targeting xCT, a cystine-glutamate antiporter: (1) an antibody-drug conjugate (xCT-mAb-ADC), (2), a conjugated radiopharmaceutical and (3) AX09.
  • xCT expression is low in normal cells but elevated in numerous cancer types corresponding to increases in intracellular reactive oxygen species (ROS).
  • AgilVax discovers and develops antibody-based therapeutics for the treatment of various cancers targeting xCT (SLC7A11), a cystine-glutamate antiporter.

Genosity Receives CLIA Approval for AsTra Profile™ and AsTra Next™ to Enable Earlier Detection of Cancer Relapse Through Patient-Specific Liquid Biopsy Monitoring

Retrieved on: 
Tuesday, August 18, 2020
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Clinical medicine, Medicine, Branches of biology, Cancer screening, Biopsy, Liquid biopsy, Laboratory techniques, Assay, Melanocytic nevus, Minimal residual disease

This fingerprint is then leveraged to generate a patient specific molecular assay using a third-party library prep technology.

Key Points: 
  • This fingerprint is then leveraged to generate a patient specific molecular assay using a third-party library prep technology.
  • Astra One, the second component of the system enables detection of the tumors unique signature and initial MRD assessment through non-invasive liquid biopsy.
  • Astra Next, the third component of this platform allows ongoing monitoring and MRD assessment through liquid biopsy as well.
  • The comprehensive platform provides an ability to detect the presence of relapse or residual disease and potentially enable earlier management interventions.

Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

Retrieved on: 
Tuesday, August 18, 2020
Other Health, General Health, Pharmaceutical, Oncology, Technology, Infectious diseases, Genetics, Public relations, Investor relations, Cardiology, Nanotechnology, Biotechnology, Communications, Health, Nucleic acids, Branches of biology, RNA, Gene expression, Molecular biology, Molecular genetics, RNA interference, Arrowhead Pharmaceuticals, RNA silencing, Small interfering RNA

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Key Points: 
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
  • RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Purigen Transforms Oncology Sample Preparation with Novel RNA Purification Kit for Challenging Clinical FFPE Specimens

Retrieved on: 
Tuesday, August 18, 2020
Software, Research, Hardware, Oncology, Technology, Medical devices, Genetics, Clinical trials, Science, Biotechnology, Medical Supplies, Other Technology, Health, Branches of biology, RNA, Biology, Biochemistry, Biotechnology, Molecular biology, Gene expression, microRNA

Purigen will present performance data showcasing how the Ionic FFPE to Pure RNA Kit can be used to evaluate gene and miRNA expression in FFPE samples during an interactive webinar on Wednesday, Aug. 19, 2020, at 1 pm ET.

Key Points: 
  • Purigen will present performance data showcasing how the Ionic FFPE to Pure RNA Kit can be used to evaluate gene and miRNA expression in FFPE samples during an interactive webinar on Wednesday, Aug. 19, 2020, at 1 pm ET.
  • View the full release here: https://www.businesswire.com/news/home/20200818005226/en/
    Purigen Ionic FFPE to Pure RNA Kit (Photo: Business Wire)
    Currently, the vast majority of clinical samples used in oncology research are stored as FFPE tissues, which often contain degraded or fragmented nucleic acids.
  • The Ionic FFPE to Pure RNA Kit will enable scientists to maximize the amount of actionable information extracted from these precious but challenging clinical samples, said Barney Saunders, PhD, CEO of Purigen Biosystems.
  • Purigen will present data and showcase its new Ionic FFPE to Pure RNA Kit during an interactive webinar hosted by Cambridge Healthtech Institute.

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics

Retrieved on: 
Tuesday, August 18, 2020
Oncology, Health, Infectious diseases, Genetics, Pharmaceutical, Biotechnology, Companies, Agilent Technologies, Hewlett-Packard, California

The expansion will more than double the current capacity for manufacturing therapeutic oligos at the Frederick site.

Key Points: 
  • The expansion will more than double the current capacity for manufacturing therapeutic oligos at the Frederick site.
  • The addition of the higher-volume manufacturing line will help Agilent meet this growing demand from leading pharmaceutical and biotech companies.
  • Agilent is investing approximately $150 million to add 25,000 square feet of manufacturing capacity to the Frederick facility.
  • The new capacity will also expand Agilents presence in Colorado, where the company has had an oligo manufacturing site in nearby Boulder since 2006.

Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors

Retrieved on: 
Tuesday, August 18, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Seattle Genetics

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W. Love, M.D., has been appointed to the companys Board of Directors.

Key Points: 
  • Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that Ted W. Love, M.D., has been appointed to the companys Board of Directors.
  • We are pleased to welcome Ted to our Board of Directors given his distinguished industry expertise and leadership, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics.
  • Concurrent with the appointment of Dr. Love, Srinivas Akkaraju, M.D., Ph.D., has resigned from the companys Board of Directors.
  • He has played an instrumental role in building Seattle Genetics to the global, multi-product company that it is today.

Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

Retrieved on: 
Tuesday, August 18, 2020
Technology, Infectious diseases, Genetics, Clinical trials, Nanotechnology, Cardiology, Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, RNA, Gene expression, Biology, Arrowhead Pharmaceuticals, RNA interference, Clear cell renal cell carcinoma, Renal cell carcinoma

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).
  • We also recently announced that ARO-ENaC, our investigational RNAi therapeutic targeting cystic fibrosis, started dosing in a Phase 1/2 study.
  • This is very exciting for us at Arrowhead and, we think, represents a significant step towards reaching the full therapeutic potential of RNA interference.
  • AROHIF21001 ( NCT04169711 ) is a Phase 1b dose-finding clinical study in up to 18 patients with advanced ccRCC to evaluate the safety of ARO-HIF2 and to determine the recommended Phase 2 dose.

Global Genes Announces Global Genes LIVE! A RARE Patient Advocacy (un)Summit

Retrieved on: 
Tuesday, August 18, 2020
Managed care, General Health, Infectious diseases, Family, Genetics, Consumer, Clinical trials, Alternative medicine, Health, Other Education, Other Health, Education, Radiology, Pharmaceutical, Stem cells, Children, Oncology, Branches of biology, Articles, Medicine, Global Genes, Rare disease, Inspire, Gene, Disease

Global Genes is pleased to announce the Global Genes LIVE!

Key Points: 
  • Global Genes is pleased to announce the Global Genes LIVE!
  • Global Genes, a leading international rare patient advocacy organization, is holding this virtual event in place of its highly anticipated annual in-person gathering.
  • Global Genes is a 501(c)(3) nonprofit organization on a mission to connect, empower, and inspire the rare disease community.
  • If you or someone you love has a rare disease or are searching for a diagnosis, contact Global Genes at 949-248-RARE or visit the resource hub at Globalgenes.org .